Ironwood Pharmaceuticals, Inc. Financials

Market Capitalization $606.5 Million as of Jan. 1, 2025

Valuations Metrics as of Jan. 25, 2025

Trailing PE	59.38
Forward PE	9.97
Price to Sales TTM	$1.60
Price to Book MRQ	$-1.90
Enterprise to Revenue	2.99
Enterprise to EBITDA	11.63

Financial Reports as of Sep. 30, 2024

Financials

Fiscal Year Ends	2023-12-31
Most Recent Quarter	2024-09-30
Profit Margin	-0.65%
Operating Margin	28.01%
Return on Assets TTM	13.05%
Return on Equity TTM	289.42%

Income Statement

Revenue TTM	$378,417,984
Revenue per Share TTM	$2.39
Quarterly Revenue Growth	-19.50%
Gross Profit TTM	$253,012,000
EBITDA	$115,114,000
Net Income to Common TTM	$-2,463,000
Diluted EPS TTM	$-0.01
Quarterly Earnings Growth YoY	-76.20%

Balance Sheet

Total Cash MRQ	$88,211,000
Total Cash per Share MRQ	$0.55
Total Debt MRQ	$
Total Debt to Equity MRQ	-1.97
Current Ratio MRQ	3.62
Book Value per Share MRQ	$-1.95

Cash Flow

Operating Cash Flow TTM	$124,169,000
Levered Free Cash Flow TTM	$79,683,952

IRWD Stock Info as of Jan. 25, 2025

Stock Statistics

Shares Outstanding	160,028,000
Float Shares	132,178,648
Avg 10 Volume	1,851,810
Avg 30 Volume	None
Shares Short	9,217,937
Short Ratio	3.78
Short % of Shares	11.13%
% Held by Insiders	1.68%
% Held by Institutions	105.13%

Stock Price Summary

Beta	0.48
Fifty Two Week Low	$3.06
Fifty Two Week High	$15.70
Fifty Two Week Change	-270.89%
Day 50 MA	$3.98
Day 200 MA	$5.37

Dividends and Splits

Forward Annual Dividend Rate	$
Forward Annual Dividend Yield	%
Trailing Annual Dividend Rate	$0.00
Trailing Annual Dividend Yield	0.00%
Payout Ratio	0.00%
Dividend Date
Ex Dividend Date
Last Split Factor
Last Split Date	2019-04-02